{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:00:04Z","timestamp":1789556404930,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.msard.2023.105052","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:44:45Z","timestamp":1696553085000},"page":"105052","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Real-world treatment patterns and effectiveness of cladribine tablets in patients with relapsing forms of multiple sclerosis in the United States"],"prefix":"10.1016","volume":"79","author":[{"given":"Yan","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Schiffon L.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danni","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manasvi","family":"Sundar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namita","family":"Tundia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2023.105052_bib0001","doi-asserted-by":"crossref","unstructured":"Arena, S., Chisari, C.G., Toscano, S., et\u00a0al., 2023. REal-World effectIveNess of claDribine for patients with multiple sclerosis: a Sicilian multicentric experience (REWIND study). Curr. Neuropharmacol. Epub ahead of print.","DOI":"10.2174\/1570159X21666230322140711"},{"issue":"8","key":"10.1016\/j.msard.2023.105052_bib0002","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1185\/03007995.2014.915802","article-title":"Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis","volume":"30","author":"Bergvall","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"issue":"1","key":"10.1016\/j.msard.2023.105052_bib0003","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40120-017-0064-x","article-title":"Comparative effectiveness research of disease-modifying therapies for the management of multiple sclerosis: analysis of a large health insurance claims database","volume":"6","author":"Boster","year":"2017","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2023.105052_bib0004","doi-asserted-by":"crossref","first-page":"104791","DOI":"10.1016\/j.msard.2023.104791","article-title":"Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: a real-world study","volume":"76","author":"Brownlee","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2023.105052_bib0006","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3111\/13696998.2010.523670","article-title":"Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims","volume":"13","author":"Chastek","year":"2010","journal-title":"J. Med. Econ."},{"issue":"5","key":"10.1016\/j.msard.2023.105052_bib0007","first-page":"639","article-title":"Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in US commercial claims data","volume":"27","author":"Engmann","year":"2021","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.msard.2023.105052_bib0008","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2147\/CEOR.S288296","article-title":"Evaluating treatment patterns, relapses, healthcare resource utilization, and costs associated with disease-modifying treatments for multiple sclerosis in DMT-na\u00efve patients","volume":"13","author":"Freeman","year":"2021","journal-title":"Clinicoecon. Outcomes Res."},{"issue":"5","key":"10.1016\/j.msard.2023.105052_bib0009","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.msard.2023.105052_bib0010","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2023.105052_bib0011","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/0272989X19897944","article-title":"Summarizing patient preferences for the competitive landscape of multiple sclerosis treatment options","volume":"40","author":"Jonker","year":"2020","journal-title":"Med. Decis. Mak."},{"issue":"3","key":"10.1016\/j.msard.2023.105052_bib0012","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/1352458520921087","article-title":"Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: an MSBase registry substudy","volume":"27","author":"Lizak","year":"2021","journal-title":"Mult. Scler."},{"issue":"9","key":"10.1016\/j.msard.2023.105052_bib0013","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/brain\/awac016","article-title":"How patients with multiple sclerosis acquire disability","volume":"145","author":"Lublin","year":"2022","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.msard.2023.105052_bib0014","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2023.105052_bib0015","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s40120-019-00156-5","article-title":"Treatment effectiveness for resolution of multiple sclerosis relapse in a US health plan population","volume":"8","author":"Nazareth","year":"2019","journal-title":"Neurol. Ther."},{"issue":"1","key":"10.1016\/j.msard.2023.105052_bib0016","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s41669-017-0035-2","article-title":"Comparison of disease-modifying therapies for the management of multiple sclerosis: analysis of healthcare resource utilization and relapse rates from US insurance claims data","volume":"2","author":"Nicholas","year":"2018","journal-title":"Pharmacoecon. Open."},{"issue":"1","key":"10.1016\/j.msard.2023.105052_bib0017","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1007\/s12325-020-01570-0","article-title":"Annual cost burden by level of relapse severity in patients with multiple sclerosis","volume":"38","author":"Nicholas","year":"2021","journal-title":"Adv. Ther."},{"issue":"6","key":"10.1016\/j.msard.2023.105052_bib0018","first-page":"469","article-title":"Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population","volume":"8","author":"Ollendorf","year":"2002","journal-title":"J. Manag. Care Pharm."},{"key":"10.1016\/j.msard.2023.105052_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102162","article-title":"A literature review of cost-of-illness studies on the economic burden of multiple sclerosis","volume":"43","author":"Paz-Zulueta","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2023.105052_bib0020","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s40120-022-00364-6","article-title":"Predictors of cladribine effectiveness and safety in multiple sclerosis: a real-world, multicenter, 2-year follow-up study","volume":"11","author":"Petracca","year":"2022","journal-title":"Neurol. Ther."},{"issue":"2","key":"10.1016\/j.msard.2023.105052_bib0021","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/13524585211012227","article-title":"Effectiveness and safety of cladribine in MS: real-world experience from two tertiary centres","volume":"28","author":"Pfeuffer","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.105052_bib0022","series-title":"Multiple sclerosis: New perspectives On the Patient Journey: 2019 Update","author":"Pyenson","year":"2019"},{"key":"10.1016\/j.msard.2023.105052_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103755","article-title":"Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study","volume":"61","author":"Rauma","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2023.105052_bib0024","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40120-020-00219-y","article-title":"Consequences of insurance denials among U.S. Patients prescribed repository corticotropin injection for acute exacerbations of multiple sclerosis","volume":"10","author":"Rice","year":"2021","journal-title":"Neurol. Ther."},{"issue":"1","key":"10.1016\/j.msard.2023.105052_bib0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s40120-018-0123-y","article-title":"Treatment patterns, healthcare resource utilization, and costs among medicare patients with multiple sclerosis in relation to disease-modifying therapy and corticosteroid treatment","volume":"8","author":"Sanchirico","year":"2019","journal-title":"Neurol. Ther."},{"issue":"3","key":"10.1016\/j.msard.2023.105052_bib0026","first-page":"105","article-title":"Safety and effectiveness of cladribine in multiple sclerosis: real-world clinical experience from 5 tertiary hospitals in Portugal","volume":"46","author":"Santos","year":"2023","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.msard.2023.105052_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104491","article-title":"Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: a Danish nationwide study","volume":"70","author":"Sorensen","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.105052_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102539","article-title":"Replication of a claims-based algorithm to estimate multiple sclerosis disease severity in a commercially insured population","volume":"46","author":"Toliver","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2023.105052_bib0005","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/13524585221137502","article-title":"Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: results from MSBase Registry","volume":"29","author":"Spelman","year":"2023","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.105052_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102741","article-title":"Use of a claims-based algorithm to estimate disease severity in the multiple sclerosis Medicare population","volume":"49","author":"Toliver","year":"2021","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823005539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823005539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T16:12:57Z","timestamp":1727453577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823005539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":29,"alternative-id":["S2211034823005539"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.105052","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world treatment patterns and effectiveness of cladribine tablets in patients with relapsing forms of multiple sclerosis in the United States","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.105052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105052"}}